Evaluation of the Progression of Disease and Health-related Quality of Life in Patients With Pulmonary Hypertension: A Local Clinic-based Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-05

Study Completion Date

2030-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pulmonary Hypertension (PH) is a multifaceted disease and is associated with significant morbidity and mortality if untreated1. Diagnosing PH can be challenging and often delayed2. Multiple international registries included REVEAL3 and COMPERA4 have all demonstrated that diagnostic delay and suboptimal treatment prescription led poor 1 year-survival in patient with PH. In recent years, significant progress has been made in diagnosing, risk stratification, and treatment for patients with PH1. A dedicated PH service has been established in ambulatory clinic to streamline the management of these complex patients. This registry therefore aims to investigate the progression disease and its impact on the quality of life (QoL) of the patients who are managed at the dedicated PH clinic.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Registry for Pulmonary Hypertension Due to Left Heart Disease in China

NCT02164526

Pulmonary Hypertension Due to Left Heart Disease

UNKNOWN

Registry for Pulmonary Hypertension in China

NCT01417338

Pulmonary Arterial Hypertension Chronic Thromboembolic Pulmonary Hypertension Death

UNKNOWN

Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension in China

NCT03185572

COPD Pulmonary Hypertension

UNKNOWN

PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension

NCT07131241

Pulmonary Hypertension

RECRUITING

Pulmonaryhypertension in Copd at Different Levels of Smoking

NCT06031311

Pulmonary Hypertension

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pulmonary Hypertension (PH) is a multifaceted disease and is associated with significant morbidity and mortality if untreated1. Diagnosing PH can be challenging and often delayed2. Multiple international registries included REVEAL3 and COMPERA4 have all demonstrated that diagnostic delay and suboptimal treatment prescription led poor 1 year-survival in patient with PH. In recent years, significant progress has been made in diagnosing, risk stratification, and treatment for patients with PH1. A dedicated PH service has been established in ambulatory clinic to streamline the management of these complex patients. This registry therefore aims to investigate the progression disease and its impact on the quality of life (QoL) of the patients who are managed at the dedicated PH clinic.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients at the Prince of Wales Hospital ambulatory cardiac clinic

Patients age \> 18 with echocardiographic confirmation of increased pulmonary pressure (eg. estimated RVSP \>40mmHg, evidence of RV dilatation etc) and able to attend at the Prince of Wales Hospital ambulatory cardiac clinic

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients age \> 18 with echocardiographic confirmation of increased pulmonary pressure (eg. estimated RVSP \>40mmHg, evidence of RV dilatation etc), and no apparent reversible causes.
* Patients with reasonable pre-morbids and is able to attend ambulatory clinic.